These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16098072)

  • 1. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
    Schmidt-Hieber M; Fietz T; Knauf W; Uharek L; Hopfenmüller W; Thiel E; Blau IW
    Br J Haematol; 2005 Aug; 130(4):568-74. PubMed ID: 16098072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
    Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
    Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
    Front Immunol; 2021; 12():749266. PubMed ID: 34621279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
    Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
    Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation.
    Jiang XY; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Sun YQ; Mo XD; Huang XJ
    Cell Transplant; 2024; 33():9636897241257568. PubMed ID: 38832653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
    Fang J; Hu C; Hong M; Wu Q; You Y; Zhong Z; Li W; Zou P; Hu Y; Xia L
    Biol Blood Marrow Transplant; 2012 May; 18(5):754-62. PubMed ID: 21963619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.
    Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ
    Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Gao Z; Fan Z; Liu Z; Ye X; Zeng Y; Xuan L; Huang F; Lin R; Sun J; Liu Q; Xu N
    Front Immunol; 2024; 15():1408211. PubMed ID: 39021571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist.
    Funke VA; de Medeiros CR; Setúbal DC; Ruiz J; Bitencourt MA; Bonfim CM; Neto JZ; Pasquini R
    Bone Marrow Transplant; 2006 May; 37(10):961-5. PubMed ID: 16565744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of anti-CD25 monoclonal antibody used in treating steroid-resistant acute graft-versus-host disease following haploidentical bone marrow transplantation].
    Liu J; Wang HX; Duan LN; Yang HM; Xue M; Zhu L; Ding L; Wang ZD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):160-3. PubMed ID: 19236770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease].
    He ZX; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Chen X; Jiang EL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):120-127. PubMed ID: 35381672
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
    van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
    Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
    Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study.
    Liu SN; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ; Mo XD
    Am J Hematol; 2020 Aug; 95(8):927-936. PubMed ID: 32311156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.
    Bay JO; Dhédin N; Goerner M; Vannier JP; Marie-Cardine A; Stamatoullas A; Jouet JP; Yakoub-Agha I; Tabrizi R; Faucher C; Diez-Martin JL; Nunez G; Parody R; Milpied N; Espérou H; Garban F; Galambrun C; Kwiatkovski F; Darlavoix I; Zinaï A; Fischer A; Michallet M; Vernant JP
    Transplantation; 2005 Sep; 80(6):782-8. PubMed ID: 16210965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
    Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
    Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Wang JZ; Liu KY; Xu LP; Liu DH; Chen YH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2008 Nov; 47(11):923-5. PubMed ID: 19080235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
    Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
    Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.